Terry Cheuk‐Fung Yip, Vincent Wai‐Sun Wong, Grace Chung‐Yan Lui, Viola Chi‐Ying Chow, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Henry Lik‐Yuen Chan, David Shu‐Cheong Hui, Grace Lai‐Hung Wong – 6 May 2021
Ravi Jhaveri, Lynn M. Yee, Swati Antala, Margaret Murphy, William A. Grobman, Seema K. Shah – 6 May 2021
Fanta Barrow, Saad Khan, Haiguang Wang, Xavier S. Revelo – 6 May 2021 – NAFLD is one of the leading causes of abnormal liver function worldwide. NAFLD refers to a group of liver conditions ranging from nonalcoholic fatty liver to NASH, which involves inflammation, hepatocellular damage, and fibrosis. Triggering of inflammation in NASH is a key event in the progression of the disease, and identifying the factors that initiate or dysregulate this process is needed to develop strategies for its prevention or treatment.
Tatyana Kushner, Catherina A. Chappell – 5 May 2021
Alessandra Gentilini, Giulia Lori, Alessandra Caligiuri, Chiara Raggi, Giovanni Di Maira, Mirella Pastore, Benedetta Piombanti, Tiziano Lottini, Annarosa Arcangeli, Stefania Madiai, Nadia Navari, Jesus M. Banales, Sabina Di Matteo, Domenico Alvaro, Lea Duwe, Jesper B. Andersen, Alessandro Tubita, Ignazia Tusa, Luca Di Tommaso, Claudia Campani, Elisabetta Rovida, Fabio Marra – 5 May 2021
Catherine A Chapin, Sarah A Taylor, Padmini Malladi, Katie Neighbors, Hector Melin‐Aldana, Portia A Kreiger, Nina Bowsher, Matthew J Schipma, Kathleen M Loomes, Edward M Behrens, Estella M Alonso – 5 May 2021 – Many patients with indeterminate pediatric acute liver failure (PALF) have evidence of T‐cell driven immune injury; however, the precise inflammatory pathways are not well defined. We have characterized the hepatic cytokine and transcriptional signatures of patients with PALF.
Binu V. John, Kaley Schwartz, Cynthia Levy, Bassam Dahman, Yangyang Deng, Paul Martin, Tamar H. Taddei, David E. Kaplan – 5 May 2021 – Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhosis. We investigated the effects of treatment with OCA on hepatic decompensation and liver‐related mortality or transplantation in a cohort with compensated PBC cirrhosis.
Murli Krishna – 4 May 2021
Hidenori Toyoda, Atsushi Hiraoka, Haruki Uojima, Akito Nozaki, Noritomo Shimada, Koichi Takaguchi, Hiroshi Abe, Masanori Atsukawa, Kentaro Matsuura, Toru Ishikawa, Shigeru Mikami, Tsunamasa Watanabe, Ei Itobayashi, Kunihiko Tsuji, Taeang Arai, Satoshi Yasuda, Makoto Chuma, Tomonori Senoh, Akemi Tsutsui, Tomomi Okubo, Takuya Ehira, Takashi Kumada, Junko Tanaka – 4 May 2021 – Hepatocellular carcinoma (HCC) can de novo develop in patients with chronic hepatitis C even after the achievement of sustained virologic response (SVR).